Cancer Immunotherapy: Expanding Frontiers

First CAR-T approval for solid tumor in China; daraxonrasib doubles pancreatic cancer survival; off-the-shelf CAR-T vispa-cel 82% ORR; bispecifics (cevostamab) and PROTAC-controlled CAR-Ts emerging. New biomarkers (TMB for neoadjuvant ICI in MIBC, TROP2 for TUSC2 gene therapy) and personalized toxicity genetics. Enzomenib orphan for ALL adds to menin inhibitor space.